Galectin Therapeutics (GALT) AI Stock Analysis

• Market Cap: $154.69M
• Dividend Yield: N/A
• Average Volume (3M): 341.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: N/A
• EPS Growth: 18.82%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 65,827,446
• 10 Day Avg. Volume: 287,288
• 30 Day Avg. Volume: 341,945
• PEG Ratio: 0.23
• Price to Book (P/B): -2.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.13
• Enterprise Value/Market Cap: 1.80
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -11.88
• 1Y Price Target: $11.00
• Price Target Upside: 92.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.41
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $2.00 ▼(-64.97% Downside)
• Action: Reiterated Date: 04/08/26
• Date: Action: Reiterated 04/08/26

The score is weighed down primarily by weak financial performance (no revenue, ongoing losses/cash burn, and a stressed balance sheet with negative equity and rising debt). Technicals also remain bearish with the stock trading below key moving averages and negative MACD. Valuation signals are limited due to losses and no dividend, while the recent board addition is a modest positive but not enough to offset the core financial and trend risks.

Positive Factors

Board scientific expertise

Adding an experienced neurosurgeon-scientist with deep translational and regulatory experience strengthens the company’s clinical governance. This enhances trial design, regulatory interactions and late-stage execution capability, reducing execution risk over the next 2–6 months.

Negative Factors

Deeply negative equity and leverage

Negative equity and sharply higher debt constrain financial flexibility and raise refinancing and covenant risks. With modest assets, the company faces higher probability of dilutive financings or strained creditor terms that could impact program timelines and strategic options.

Galectin Therapeutics Business Overview & Revenue Model

Company Description

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibit...

Read more

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibit...

How the Company Makes Money

As a clinical-stage biotechnology company, Galectin Therapeutics does not have publicly established, recurring product revenue from commercialized drugs; its business model is primarily centered on advancing drug candidates through clinical trials...

Read more

As a clinical-stage biotechnology company, Galectin Therapeutics does not have publicly established, recurring product revenue from commercialized drugs; its business model is primarily centered on advancing drug candidates through clinical trials...

Galectin Therapeutics Financial Statement Overview

Breakdown	Mar 2026	Mar 2025	Dec 2023	Dec 2022	Mar 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-37.00K	-33.00K	-32.00K	-41.00K
EBITDA	-23.45M	-41.47M	-38.24M	-37.71M	-30.00M
Net Income	-30.84M	-47.05M	-41.07M	-38.78M	-30.53M
Balance Sheet
Total Assets	19.53M	17.50M	28.20M	21.29M	41.83M
Cash, Cash Equivalents and Short-Term Investments	17.72M	15.12M	25.66M	18.59M	39.65M
Total Debt	133.74M	106.25M	71.81M	39.87M	29.06M
Total Liabilities	145.73M	120.56M	88.44M	53.48M	39.21M
Stockholders Equity	-126.19M	-103.07M	-60.24M	-32.19M	2.62M
Cash Flow
Free Cash Flow	-23.88M	-41.77M	-32.97M	-31.06M	-24.31M
Operating Cash Flow	-23.88M	-41.77M	-32.97M	-31.06M	-24.31M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	26.48M	31.23M	40.03M	10.00M	36.81M

Galectin Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Negative. The current price of 5.71 is above the 20-day moving average (MA) of 2.68, above the 50-day MA of 2.86, and above the 200-day MA of 3.95, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 38.99 is Neutral, neither overbought nor oversold. The STOCH value of 24.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GALT.

Galectin Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JBIO	55 Neutral	$911.86M	-3.80	-50.23%	14.68%	―	89.16%
TECX	54 Neutral	$562.55M	-5.15	-26.87%	―	―	60.40%
OMER	53 Neutral	$819.32M	3.16	1.71%	―	―	12.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYGR	47 Neutral	$228.86M	-1.93	-51.35%	―	-80.88%	-388.61%
TNYA	44 Neutral	$155.22M	-1.20	-85.20%	―	―	46.68%
GALT	43 Neutral	$154.69M	-8.62	25.65%	―	―	18.82%

Galectin Therapeutics Corporate Events